Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AS03-adjuvanted low-dose seasonal influenza vaccine
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The AS03-adjuvanted low-dose seasonal influenza vaccine is an investigational biologic developed by GSK designed to prevent seasonal influenza infection. It consists of a low-dose inactivated split-virion trivalent influenza vaccine (TIV) formulated with the proprietary AS03 adjuvant system. AS03 is an oil-in-water emulsion containing squalene, alpha-tocopherol (tocopherol), and polysorbate-80, which acts to enhance the magnitude and breadth of the immune response. This formulation is specifically designed for antigen dose-sparing, allowing for effective immunization with a significantly lower amount of viral hemagglutinin (HA) antigen compared to standard non-adjuvanted vaccines. It has been evaluated in Phase II clinical trials in healthy adults to assess its immunogenicity, safety, and reactogenicity against standard seasonal vaccines like Fluarix.
- Other names
- AS03-adjuvanted trivalent inactivated influenza vaccineAS-03-adjuvanted trivalent inactivated influenza vaccineAS 03-adjuvanted trivalent inactivated influenza vaccinelow-dose AS03-adjuvanted TIV
02
Targets
HA (Hemagglutinin)Neuraminidase
Beyond the preview
Go deeper on AS03-adjuvanted low-dose seasonal influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AS03-adjuvanted low-dose seasonal influenza vaccine.